A Variant in the Neuropeptide S Receptor Gene Is Linked to Schizophrenia and Affects Memory and Startle Response | Research

The takeaway

A genetic variant in the neuropeptide S receptor (NPSR1) that reduces receptor function was associated with schizophrenia and impaired verbal memory consolidation in 778 patients.

OR 1.19, p=0.017
The low-functioning NPSR1 Asn107 variant was significantly more common in schizophrenia patients, suggesting reduced neuropeptide S signaling is a risk factor

What the researchers found

The low-functioning NPSR1 Asn107 variant was significantly associated with schizophrenia (OR 1.19, p=0.017) in a case-control sample of 778 schizophrenia patients vs. 713 healthy controls. Patients homozygous for the Asn107 variant showed specifically decreased verbal memory consolidation (while memory acquisition was unaffected). Patients carrying the high-functioning Ile107 variant had significantly reduced startle amplitudes but unaffected prepulse inhibition and habituation.

These findings translate rodent NPS research into human psychiatric genetics — confirming that NPS receptor function affects both memory and startle response in schizophrenia patients, consistent with animal model predictions.

Why it matters

Schizophrenia treatment has been dominated by dopamine-blocking antipsychotics since the 1950s, with limited progress on cognitive symptoms. This study identifies the neuropeptide S system as a potential new drug target for schizophrenia — specifically for the cognitive deficits (like memory problems) that current medications don't address well. The translation from rodent models to human genetic data strengthens the case for NPS-based drug development.

The numbers in context

n=778 schizophrenia patients + 713 controls · OR 1.19, p=0.017 · Asn107Ile variant (rs324981) · Verbal memory consolidation affected · Startle amplitude reduced in Ile107 carriers

How the study worked

Case-control genetic association study. 778 schizophrenia patients and 713 healthy controls were genotyped for the NPSR1 Asn107Ile variant (rs324981). Subsamples of patients underwent cognitive testing (verbal declarative memory) and acoustic startle response measurement, with results stratified by genotype.

What this study cannot tell us

The odds ratio (1.19) is small, typical of common psychiatric genetic variants but indicating a modest effect size. The study was conducted in a single ethnic population (German), limiting generalizability. Memory and startle testing were done in patient subsamples rather than the full cohort. The association does not prove causation — the variant could be in linkage disequilibrium with the true causal variant.

How to read the evidence

This is a moderately sized case-control genetic association study (n=1,491) with appropriate control group and cognitive phenotyping. The effect size is small (OR 1.19) but consistent with known psychiatric genetics. Replication in independent populations would strengthen the finding.

When this study was published

Published in 2012, this was an early study linking NPS genetics to schizophrenia. The NPS system remains an active area of psychiatric research, though NPS-targeted drugs have not yet reached clinical trials for schizophrenia.

The bigger picture

The NPS system was already linked to panic disorder through the same Asn107Ile variant, and animal studies showed NPS could block NMDA antagonist-induced deficits (relevant to schizophrenia models). This study extends NPS genetics into schizophrenia, connecting a neuropeptide system to both anxiety disorders and psychotic illness. It adds to the growing recognition that neuropeptides — beyond the classical dopamine/serotonin/glutamate targets — may play important roles in psychiatric disorders and could yield new classes of medications.

Questions still open

Could NPS receptor agonists improve cognitive deficits in schizophrenia patients, particularly verbal memory?
Does the NPSR1 Asn107Ile variant influence treatment response to current antipsychotic medications?
Is the NPS system involved in other cognitive symptoms across different psychiatric disorders?

Common questions

What is neuropeptide S and what does it do in the brain?

Neuropeptide S (NPS) is a brain signaling molecule that reduces anxiety, enhances memory, and promotes wakefulness in animal studies. It works through a specific receptor (NPSR1). Some people carry a genetic variant that makes this receptor less effective — and this study found that variant is more common in people with schizophrenia.

Could this lead to new schizophrenia treatments?

Potentially. Current antipsychotics mainly target dopamine and don't help much with cognitive problems like memory deficits. If reduced NPS signaling contributes to these cognitive symptoms, then drugs that boost NPS receptor activity could address an unmet need. However, no NPS-targeting drugs have been developed for human use yet.

Read the original research

The functional coding variant Asn107Ile of the neuropeptide S receptor gene (NPSR1) is associated with schizophrenia and modulates verbal memory and the acoustic startle response.

The international journal of neuropsychopharmacology, 15(9), 1205-15

View on PubMed ↗Publisher’s paper ↗

Citation

Lennertz, Leonhard; Quednow, Boris B; Schuhmacher, Anna; Petrovsky, Nadine; Frommann, Ingo; Schulze-Rauschenbach, Svenja; Landsberg, Martin W; Steinbrecher, Anja; Höfels, Susanne; Pukrop, Ralf; Klosterkötter, Joachim; Franke, Petra E; Wölwer, Wolfgang; Gaebel, Wolfgang; Häfner, Heinz; Maier, Wolfgang; Wagner, Michael; Mössner, Rainald. (2012). The functional coding variant Asn107Ile of the neuropeptide S receptor gene (NPSR1) is associated with schizophrenia and modulates verbal memory and the acoustic startle response.. The international journal of neuropsychopharmacology, 15(9), 1205-15. https://doi.org/10.1017/S1461145711001623